Full Name
Cytotoxic T-Lymphocyte Associated Protein 4
Alternative Names
Ipilimumab; yervoy; 477202-00-9; MDX-010; MDX-101; Yervoy; MDX-010; MDX-101; CTLA4; cytotoxic T-lymphocyte-associated protein 4; celiac disease 3, CELIAC3; cytotoxic T-lymphocyte protein 4; CD; CD28; CD152; GSE; ICOS; CD152 isoform; celiac disease 3;
Cellular Localization
Plasma membrane
Involvement in Disease
Its related pathways are TCR Signaling (Qiagen) and T cell receptor signaling pathway.
Related Pathways
Inhibitory receptor acting as a major negative regulator of T-cell responses. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28.
Field of research
N-glycosylation is important for dimerization. Phosphorylation at Tyr-201 prevents binding to the AP-2 adapter complex, blocks endocytosis, and leads to retention of CTLA4 on the cell surface.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Clone
Ticilimumab (= Tremelimumab)
Description
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CTLA4. Tremelimumab (formerly ticilimumab, CP-675,206) is a fully human IgG2 monoclonal antibody, undergoing human trials for the treatment of cancer.
Indication
Melanoma, metastatic
